Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company: It's Wait And See For Me
Becton, Dickinson and Company is a leading medical device firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. BDX operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, with plans to spin off its Biosciences and Diagnostic Solutions business in 2026. BDX has struggled over the past decade, with a 10-year CAGR of only 5.1%.
BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair
Phasixâ„¢ ST Umbilical Hernia Patch Leverages Same Surgical Technique as Permanent Mesh Procedures FRANKLIN LAKES, N.J. , April 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasixâ„¢ ST Umbilical Hernia Patch, the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
DGI For The DIY: 2024 Dividend Portfolio Review
This portfolio focuses on generating a growing stream of dividend income by investing in companies that consistently increase dividends. I reinvest dividends into more shares of the companies I already own to compound growth. The investment strategy is guided by specific principles to ensure consistent and disciplined investing.
BD Seeks Potential Buyers for Life Sciences Business Division
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
BD to Announce Financial Results for its Second Quarter of Fiscal 2025
FRANKLIN LAKES, N.J. , April 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
​Becton Dickinson in talks to divest life sciences unit, FT reports
Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , the Financial Times reported on Tuesday.
BD Named One of America's Most Innovative Companies by Fortune
FRANKLIN LAKES, N.J. , March 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of companies overall.
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipeline. The firm is a proven dividend grower and cashflow generator with low debt/equity and investment-grade credit ratings.
BD Names Gregory J. Hayes to Board of Directors
FRANKLIN LAKES, N.J. , March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J.
BDX Stock Declines Following Class I Classification for Alaris Recall
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
